Device Trial Radar · NCT05607771
DaVitri: Semi-Automated Vitrificacion Clinical Study
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
72
Planned (sponsor's estimate)
Start
Jul 20, 2023
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Overture LifeNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 7, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Single group
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated device
- No
- Who can join
- Female only, from 30 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of this clinical study is to demonstrate the non-inferiority of the semi automated device (DaVitri) developed by Overture Life in the preparation procedures for vitrification of human samples.
Conditions
- Fertility Issues
Interventions
Manual VitrificationDevice
Oocytes will be prepared for vitrification using the manual protocol
Automated VitrificationDevice
Oocytes will be prepared for vitrification using the DaVitri device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Thaw survival rates of oocytesTime frame: Day 1
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
WeFIV Buenos Aires
Buenos Aires, Argentina
Halitus Instituto Médico
Buenos Aires, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.